Intravitreal sustained-release ganciclovir implants for severe bilateral cytomegalovirus retinitis after stem cell transplantation

Acta Ophthalmol Scand. 2002 Feb;80(1):101-4. doi: 10.1034/j.1600-0420.2002.800121.x.

Abstract

Purpose: To describe the treatment of cytomegalovirus (CMV) retinitis with intravitreal sustain-release ganciclovir devices in a 16-year-old patient in third remission of acute lymphoblastic leukemia after stem cell transplantation.

Methods: The patient received a stem cell transplant from an unrelated bone marrow donor after which he contracted a serious CMV infection manifested in the lungs and retinae. His immune system at this time was almost completely depleted. Implantation of a sustained-release ganciclovir device was performed in both eyes when retinitis progressed in spite of aggressive antiviral intravenous treatment.

Results: No per- or postoperative complications were noted. Infiltrates, hemorrhages and macular edema present preoperatively dissolved over a period of six months. The final visual acuity was 1.0 in both eyes. The patients immune system and lung function slowly recovered during the same time period.

Conclusions: The intravitreal ganciclovir implant provides safe and effective therapy against CMV retinitis, and should be considered in patients acquiring the infection after stem cell transplantation.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antiviral Agents / administration & dosage*
  • Cytomegalovirus Retinitis / drug therapy*
  • Cytomegalovirus Retinitis / etiology
  • Drug Implants
  • Ganciclovir / administration & dosage*
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Immune System / physiology
  • Immunosuppression Therapy
  • Lung / physiology
  • Male
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / etiology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Vitreous Body

Substances

  • Antiviral Agents
  • Drug Implants
  • Ganciclovir